Mpm Bioimpact LLC
About Mpm Bioimpact LLC’s 13F portfolio
Mpm Bioimpact LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Mpm Bioimpact LLC reported $1.6B across 37 US-listed positions (). Its largest position is Cullinan Therapeutics, Inc. (CGEM) at 11% of the reported book, and its ten biggest holdings make up 55% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: CGEM Cullinan Therapeutics, Inc. | $9.01 −2.86% | 11% | 9.7M | $177.2M |
| 2 | NASDAQ: AKTS Aktis Oncology, Inc. | — — | 9.5% | 4.8M | $155.9M |
| 3 | NASDAQ: LQDA Liquidia Corporation | $56.40 −0.58% | 6.7% | 1.4M | $110.5M |
| 4 | NASDAQ: RVMD Revolution Medicines, Inc. | $159.82 −1.76% | 5.6% | 492K | $92.2M |
| 5 | NASDAQ: CORT Corcept Therapeutics, Inc. | $67.79 −3.25% | 4.1% | 771K | $67.0M |
| 6 | NASDAQ: EWTX Edgewise Therapeutics Inc | $41.37 −1.59% | 4.0% | 1.6M | $65.9M |
| 7 | NASDAQ: TVTX Travere Therapeutics Inc | $50.24 −1.68% | 3.9% | 1.1M | $63.8M |
| 8 | NASDAQ: DBVT DBV Technologies S A | $9.68 −3.10% | 3.7% | 3.7M | $60.1M |
| 9 | NASDAQ: TRVI Trevi Therapeutics Inc | $13.51 0.00% | 3.5% | 3.1M | $57.3M |
| 10 | NASDAQ: ALMS Alumis Inc | $4.40 −9.19% | 3.5% | 2.0M | $56.8M |
| 11 | NASDAQ: QURE Uniqure NV | $20.30 −2.31% | 3.4% | 1.2M | $56.5M |
| 12 | NASDAQ: RARE Ultragenyx Pharmaceuticals, Inc. | $17.73 +6.17% | 2.9% | 1.4M | $47.4M |
| 13 | NASDAQ: RLAY Relay Therapeutics Inc. | $16.51 +0.24% | 2.8% | 2.4M | $45.2M |
| 14 | NASDAQ: ABVX Abivax SA | $83.83 +2.11% | 2.7% | 336K | $44.8M |
| 15 | NASDAQ: DYN Dyne Therapeutics, Inc. | $15.87 −0.94% | 2.6% | 1.9M | $42.7M |
| 16 | NASDAQ: DNTH Dianthus Therapeutics Inc | $83.98 −3.45% | 2.5% | 420K | $40.9M |
| 17 | NASDAQ: BIOA BIOAGE Labs Inc | $4.77 −6.47% | 2.5% | 1.7M | $40.9M |
| 18 | NASDAQ: URGN Urogen Pharma Ltd | $29.79 −0.27% | 2.1% | 933K | $34.3M |
| 19 | NASDAQ: MLTX MoonLake Immunotherapeutics | $10.79 −4.09% | 1.9% | 1.6M | $31.3M |
| 20 | NASDAQ: PVLA Palvella Therapeutics Inc | $146.58 +1.54% | 1.9% | 204K | $31.2M |
| 21 | NASDAQ: TSHA Taysha Gene Therapies, Inc. | $3.99 −0.25% | 1.9% | 4.5M | $30.6M |
| 22 | NASDAQ: SNDX Syndax Pharmaceuticals Inc | $8.56 −6.96% | 1.8% | 1.3M | $29.2M |
| 23 | NASDAQ: GLUE Monte Rosa Therapeutics Inc | $9.07 0.00% | 1.7% | 1.2M | $28.1M |
| 24 | NASDAQ: ZURA Zura Bio Ltd. | $0.97 −6.75% | 1.6% | 4.5M | $26.4M |
| 25 | NASDAQ: NTRA Natera Inc | $289.50 +0.71% | 1.5% | 93K | $25.1M |
Showing 1–25 of 37 positions on this page reported in this 13F.
- Healthcare90%
- AddedCGEMCullinan Therapeutics, Inc.+27.2%$177.2M
- NewRAREUltragenyx Pharmaceuticals, Inc.—$47.4M
- AddedRLAYRelay Therapeutics Inc.+2.4%$45.2M
- AddedABVXAbivax SA+214%$44.8M
- AddedDYNDyne Therapeutics, Inc.+36.5%$42.7M
- NewBIOABIOAGE Labs Inc—$40.9M
- NewTSHATaysha Gene Therapies, Inc.—$30.6M
- NewZURAZura Bio Ltd.—$26.4M
- NewANLAdlai Nortye Ltd—$22.3M
- AddedBLTEBelite Bio Inc+55.8%$21.1M
- ReducedLQDALiquidia Corporation−1.4%$110.5M
- ReducedRVMDRevolution Medicines, Inc.−2.8%$92.2M
- ReducedCORTCorcept Therapeutics, Inc.−21.8%$67.0M
- ReducedEWTXEdgewise Therapeutics Inc−2.4%$65.9M
- ReducedTVTXTravere Therapeutics Inc−0.9%$63.8M
- ReducedDBVTDBV Technologies S A−29.7%$60.1M
- ReducedTRVITrevi Therapeutics Inc−6.8%$57.3M
- ReducedALMSAlumis Inc−15.4%$56.8M
- ReducedQUREUniqure NV−10.5%$56.5M
- ReducedDNTHDianthus Therapeutics Inc−0.9%$40.9M
Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.
| # | Stock | Type | % of class | Shares | Filed |
|---|---|---|---|---|---|
| 1 | CNTX Context Therapeutics Inc. | 13G | 11.6% | 10.7M | Filed 17 FEB 2026 |
| 2 | CLYM Climb Bio, Inc. | 13G | 5.6% | 2.7M | Filed 17 FEB 2026 |
Showing all 2 disclosed stakes.
Reading Mpm Bioimpact LLC’s 13F portfolio
Mpm Bioimpact LLC’s $1.6B 13F book is spread across 37 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 55%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are CGEM, AKTS, LQDA, RVMD and CORT, led by Cullinan Therapeutics, Inc. (CGEM) at 11% of the portfolio. The heaviest sector exposure is Healthcare (90%).
What Mpm Bioimpact LLC changed last quarter
Between 2026-03-31 and Q2 2026, Mpm Bioimpact LLC was a net seller: it opened 7 new positions and added to 7 more, while trimming 22 and closing 11 outright. Against a 37-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was Cullinan Therapeutics, Inc. (CGEM), and its biggest reduction was Liquidia Corporation (LQDA).
What a 13F does and doesn’t reveal
A 13F captures only Mpm Bioimpact LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Mpm Bioimpact LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Mpm Bioimpact LLC's profile on this page is built directly from those filings.
How current is the 13F data on Mpm Bioimpact LLC's page?
It reflects Mpm Bioimpact LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Mpm Bioimpact LLC files its next quarterly report, this page refreshes automatically.
Can I see Mpm Bioimpact LLC's complete list of holdings?
This page highlights Mpm Bioimpact LLC's largest positions rather than all 37 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Mpm Bioimpact LLC's filings.
Does a 13F show everything Mpm Bioimpact LLC owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Mpm Bioimpact LLC's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Mpm Bioimpact LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

